Moderna shares surge on positive cancer vaccine trial

Moderna shares more than doubled after the US drugmaker reported positive late-stage results for a personalized mRNA skin cancer vaccine developed with Merck. The treatment reduced cancer recurrence and the spread of tumors when combined with Merck’s Keytruda, compared with Keytruda alone. Subscribe to us on YouTube: http://ow.ly/Zvqj30aIsgY Follow us on: Facebook: https://www.facebook.com/cgtnafrica/ Twitter: https://twitter.com/cgtnafrica Instagram: https://www.instagram.com/cgtn_africa/